Company profile
XENON PHARMACEUTICALS INC.
NASDAQ:XENEBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AZETUKALNER | phase3 | — | 11 | active |
| EZOGABINE | phase3 | — | 13 | completed, terminated, withdrawn |
| FUNAPIDE | phase2 | — | 5 | no active trials |
| ZANDATRIGINE | phase1 | — | 5 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (23)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01195636 | phase2 | completed | 2010-08-01 | 2011-03-01 | Xenon Pharmaceuticals Inc. | A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) |
| NCT07172516 | phase3 | recruiting | 2025-08-08 | 2028-06-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) |
| NCT06775379 | phase3 | recruiting | 2024-12-20 | 2026-08-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder |
| NCT07076407 | phase3 | recruiting | 2025-07-08 | 2027-05-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) |
| NCT05614063 | phase3 | completed | 2022-11-18 | 2026-01-12 | Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures |
FDA applications (0)
No records yet.